由维生素K缺乏或抗体II诱导的蛋白质:迄今为止的经验和未来的方向
Libin Dong1, Xun Qiu1, Fengqiang Gao1
1Zhejiang University School of Medicine, Hangzhou 310058, China; Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China.
由维生素K缺乏或对抗剂II (PIVKA-II) 诱导的蛋白质显示为肝细胞癌 (HCC) 诊断和预后的生物标志物具有前途. 对PIVKA-II的进一步研究可以推进精准医学和肝癌的治疗策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 医学诊断 医学诊断 医学诊断
背景情况:
- 肝细胞癌 (HCC) 是癌症死亡的主要原因.
- 有效的生物标志物对于HCC的精准医学至关重要.
- 由于缺乏维生素K或抗体II (PIVKA-II) 诱导的蛋白在HCC中过度表达.
研究的目的:
- 审查PIVKA-II在HCC中的多方面的作用.
- 评估PIVKA-II在诊断,预后和治疗中的实用性.
- 突出PIVKA-II作为一个潜在的治疗目标.
主要方法:
- 对PIVKA-II在HCC中的应用进行文献综述.
- 对PIVKA-II的诊断和预后价值的分析.
- 评估PIVKA-II在治疗疗效和治疗开发中的作用.
主要成果:
- 虽然PIVKA-II有助于查和诊断HCC,但不是唯一的.
- 与其他生物标志物的联合检测提高了诊断准确度.
- PIVKA-II预测了预后,移植资格,切除能力和复发情况.
- PIVKA-II还表明了维生素K的状态.
结论:
- PIVKA-II是HCC诊断,预后和治疗监测的有价值的生物标志物.
- 结合的生物标志物策略可以改善HCC检测.
- 皮夫卡-II具有开发新型治疗剂的潜力.
- 继续探索PIVKA-II对于推进HCC治疗至关重要.
更多相关视频
12:55A Microphysiological System to Study Leukocyte-Endothelial Cell Interaction during Inflammation
Published on: December 9, 2021
08:18Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions
Published on: October 4, 2024
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care
Vitamins
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
